Home
Development Programs
Team
For Investors
News
About Us
- Our Name & Brandmark
Contact

opioid

Investor Webinar | Emyria validated care model

Jun 09, 2021

Investor Webinar | Emyria validated care model

Search

Search for:

Blog
Investor
News

Tag Cloud

bioavailability blog CBD clinical research dr alistair vickery drug development EMD EMD-RX5 emd-rx7 emyria investor mdma mdma analogue program medicinal cannabis news opioid over the counter psychological conditions psychological distress screening results

Have Questions?

If you have any question, please feel free to get in touch with us.

Contact Us

Phone 08 6559 2800

Email info@emyria.com

For Investors

Stock Information
ASX Announcements
Presentations & Videos
Reports
Corporate Governance

Recent Tweets

$EMD has great partners supporting our Phase 1 trial for EMD-RX5. CMAX Clinical Research has completed dosing and n… https://t.co/izIFQr44Hc

This week, insightSBS looked at medicinal cannabis and psychedelics as possible treatments for mental illnesses an… https://t.co/5Uj07UEZhI

©2020 Emyria Limited | Terms | Privacy | Website by Glide

First Name*
Last Name*
Email*
Post code
What news are you interested in?*
- Clinical news
- Patient news
- Investor news
- Partners news
Phone
This field is for validation purposes and should be left unchanged.

Search for:

Hit enter to search or ESC to close

Home
Development Programs
Team
For Investors
News
About Us
- Our Name & Brandmark
Contact

Call 1300 436 363 Contact